Here are five things to know.
- While industry sources did not identify the entity interested in purchasing the business, they did estimate the deal could be worth as much as $2.5 billion, reported WSJ.
- The Canadian drugmaker acquired the eye-surgery business in 2013 through the acquisition of Bausch & Lomb.
- The eye unit sells lasers, tools and other equipment used in surgeries for glaucoma and cataracts, among other conditions.
- Valeant is also in talks with Japan-based Takeda Pharmaceuticals to sell its stomach drug unit, Salix Pharmaceuticals, for an estimated $10 million.
- The drugmaker is sitting on a $30 billion debt pile, which includes $12 billion in bank loans.
More articles on supply chain:
The election and slowing drug sales: 6 things to know about the rocky week for big pharma
Pfizer ditches cholesterol drug development over lack of commercial potential
Valeant eyes potential $10B deal with Takedo to sell stomach drug business
